PL1885734T3 - Immunogeny dla szczepionek przeciwko Meningitidis-A - Google Patents

Immunogeny dla szczepionek przeciwko Meningitidis-A

Info

Publication number
PL1885734T3
PL1885734T3 PL06765581T PL06765581T PL1885734T3 PL 1885734 T3 PL1885734 T3 PL 1885734T3 PL 06765581 T PL06765581 T PL 06765581T PL 06765581 T PL06765581 T PL 06765581T PL 1885734 T3 PL1885734 T3 PL 1885734T3
Authority
PL
Poland
Prior art keywords
meningitidis
immunogens
vaccines
Prior art date
Application number
PL06765581T
Other languages
English (en)
Inventor
Stefan Stockholm University Oscarson
Peter Stockholm University Teodorovic
Paolo Novartis Vaccines Costantino
Original Assignee
Novartis Ag
Oscarson Stefan
Teodorovic Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36942242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1885734(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Oscarson Stefan, Teodorovic Peter filed Critical Novartis Ag
Publication of PL1885734T3 publication Critical patent/PL1885734T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06765581T 2005-05-06 2006-05-08 Immunogeny dla szczepionek przeciwko Meningitidis-A PL1885734T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67828905P 2005-05-06 2005-05-06
EP06765581.1A EP1885734B1 (en) 2005-05-06 2006-05-08 Immunogens for meningitidis-a vaccines
PCT/IB2006/001703 WO2006120576A2 (en) 2005-05-06 2006-05-08 Immunogens for meningitidis-a vaccines

Publications (1)

Publication Number Publication Date
PL1885734T3 true PL1885734T3 (pl) 2015-08-31

Family

ID=36942242

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06765581T PL1885734T3 (pl) 2005-05-06 2006-05-08 Immunogeny dla szczepionek przeciwko Meningitidis-A

Country Status (15)

Country Link
US (1) US8062641B2 (pl)
EP (1) EP1885734B1 (pl)
JP (2) JP2008540398A (pl)
CN (1) CN101282984B (pl)
AU (1) AU2006245440B2 (pl)
BR (1) BRPI0611447A2 (pl)
CA (1) CA2606890C (pl)
ES (1) ES2533248T3 (pl)
MX (1) MX2007013881A (pl)
NZ (1) NZ563940A (pl)
PL (1) PL1885734T3 (pl)
PT (1) PT1885734E (pl)
RU (1) RU2412944C2 (pl)
WO (1) WO2006120576A2 (pl)
ZA (1) ZA200710558B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2584927T7 (es) 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Derivados de oligosacáridos sulfatados novedosos
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CN102417521B (zh) * 2010-09-28 2014-05-07 中国医学科学院医药生物技术研究所 一种非环核苷类抗病毒药物磷酸单酯化合物的制备方法
US10010616B2 (en) 2011-01-28 2018-07-03 Purdue Research Foundation Immunogenic compositions and reagents for preparing
US9616139B2 (en) 2011-07-12 2017-04-11 The General Hospital Corporation Conjugating amines
RU2476444C1 (ru) * 2011-07-15 2013-02-27 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА НОНА-β-(1→3)-ГЛЮКОЗИДА С БЫЧЬИМ СЫВОРОТОЧНЫМ АЛЬБУМИНОМ СКВАРАТНЫМ МЕТОДОМ
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
JP6416249B2 (ja) * 2013-07-07 2018-10-31 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー ストレプトコッカス ニューモニエ１型に対する合成ワクチン
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160124802A (ko) * 2014-02-25 2016-10-28 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 네이세리아 메닝기티디스 혈청군 x의 신규한 합성 올리고머 및 이의 제조 방법
TN2017000126A1 (en) * 2014-10-09 2018-10-19 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
WO2018173068A1 (en) * 2017-03-21 2018-09-27 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A novel synthetic neisseria meningitidis serogroup a oligomer and process for synthesizing thereof
MX2021005949A (es) 2018-11-22 2021-07-06 Idorsia Pharmaceuticals Ltd Vacuna estable contra clostridium difficile.
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN118178643B (zh) * 2024-04-28 2024-11-29 亚培烯科技(上海)有限公司 饱和α烯烃低聚物作为佐剂在动物疫苗中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US6114309A (en) * 1997-11-21 2000-09-05 Incara Research Laboratories Combinatorial library of moenomycin analogs and methods of producing same
JP4774496B2 (ja) * 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
ES2616180T3 (es) * 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
RU2250113C2 (ru) * 2003-06-04 2005-04-20 Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова Российской академии наук Способ приготовления бивалентной вакцины для профилактики менингококковой инфекции

Also Published As

Publication number Publication date
BRPI0611447A2 (pt) 2010-09-08
JP2008540398A (ja) 2008-11-20
NZ563940A (en) 2010-11-26
JP2013136639A (ja) 2013-07-11
WO2006120576A2 (en) 2006-11-16
ZA200710558B (en) 2010-04-28
AU2006245440A1 (en) 2006-11-16
CA2606890C (en) 2014-02-04
EP1885734A2 (en) 2008-02-13
ES2533248T3 (es) 2015-04-08
CN101282984B (zh) 2013-05-08
AU2006245440B2 (en) 2012-04-19
PT1885734E (pt) 2015-03-04
MX2007013881A (es) 2008-10-22
US8062641B2 (en) 2011-11-22
CN101282984A (zh) 2008-10-08
WO2006120576A3 (en) 2007-07-12
JP5699174B2 (ja) 2015-04-08
RU2412944C2 (ru) 2011-02-27
EP1885734B1 (en) 2015-01-14
US20090304734A1 (en) 2009-12-10
RU2007145219A (ru) 2009-06-20
CA2606890A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ZA200710558B (en) Immunogens for meningitidis-a vaccines
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
IL188072A0 (en) Process for manufacturing vaccines
GB0513421D0 (en) Vaccines
GB0522765D0 (en) Combination vaccine manufacture
ZA200711074B (en) Process for manufacturing vaccines
GB0616306D0 (en) Vaccines
EP1941278A4 (en) OPTIMAL POLYVALENT VACCINE FOR CANCER
TWI372145B (en) Process for preparing alkylanilides
GB0524409D0 (en) Vaccines
ZA200709207B (en) Vaccine
GB0810662D0 (en) Vaccine
GB0524408D0 (en) Vaccines
GB0515135D0 (en) Vaccine
GB0516944D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0614460D0 (en) Vaccines
GB0511203D0 (en) Vaccines
EP1976858A4 (en) PROCESS FOR THE PREPARATION OF 4-DEMETHYLDAUNORUBICIN
GB0526412D0 (en) Vaccine
GB0524407D0 (en) Vaccines
GB0510280D0 (en) Vaccines
IL186591A0 (en) Vaccine
GB0515242D0 (en) Vaccine